Rapid Point-of-Care Test to Detect Bacteriuria and Confirm Urinary Tract Infection

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44DK085767-02
Agency Tracking Number: R44DK085767
Amount: $1,000,000.00
Phase: Phase II
Program: SBIR
Awards Year: 2011
Solitcitation Year: 2011
Solitcitation Topic Code: NIDDK
Solitcitation Number: PA10-050
Small Business Information
SILVER LAKE RESEARCH CORPORATION
911 S PRIMROSE AVE, STE N, MONROVIA, CA, 91016-8403
Duns: 874892821
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 MARK GEISBERG
 (626) 359-8441
 mgeisberg@silverlakeresearch.com
Business Contact
 MARK GEISBERG
Phone: (626) 359-8441
Email: mgeisberg@silverlakeresearch.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): This proposal describes Phase II of the development of a rapid point-of-care test kit for the direct measurement of bacteriuria as a diagnostic for urinary tract infections (UTIs). While bacteriuria at a level of 105 CFU/ml is the gold standard for UTI diagnosis, in practice the required urine culture is unfeasible due to the typical 2-day delay in obtaining results. UTI diagnosis is aided by other in-office urinalysis dipsticks, but studies have shown that there is a high rate of misdiagnosis and consequent overtreatment with antibiotics. The proposed test kit will allow, for the first time, a direct dipstick measurement of bacterial concentration in urine within 10 minutes, in time to aid diagnosis of UTI during the initial office visit. The proposed test kit will be a lateral flow immunoassay, similar to a home pregnancy test. In the test design, multiple anti-bacteria monoclonal antibodies (MAbs) will be used to directly bind to bacterial cells in a urine sample, producing a visual +/- result calibrated to ~105 CFU/ml. These MAbs will be selected from the Company's existing collection of gt80 such antibodies. The test utilizes the Company's proprietary SandwichPLUS format, which allows the simultaneous use of multiple antibodies in a single assay and radically shortens development time. In Phase I, the applicant developed a proof-of- concept prototype which was shown to detect six uropathogenic bacteria strains at the target level of 104 - 105 CFU/ml. In Phase II, thetest kit will be further optimized for sensitivity and specificity using a much broader range of uropathogenic isolates, and test procedure will be further improved and simplified. Clinical validation studies will be carried out to determine the real-world performance of the product. At the successful conclusion of Phase II, the test kit will be ready for manufacturing, FDA review, and marketing. The estimated cost of the test to the end user will be 2.00 - 5.00 per test, far less than the cost of urineculture and in line with the cost of current urine dipsticks. PUBLIC HEALTH RELEVANCE: Urinary tract infections are some of the most common cause of physicians' office visits, accounting for over 8,000,000 visits per year in the US. The gold-standard diagnostic method for UTI, urine culture to detect bacteria, is not currently feasible as a routine procedure due to the 2-day delay in obtaining results. This proposal continues the development a simple, inexpensive, 10-minute dipstick test for bacteria in urine, to give physicians the ability to accurately diagnose UTI during the initial office visit by the patient.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government